Abdera Therapeutics
Bernd O. Keller is an accomplished analytical chemist with extensive experience in both academia and industry. Currently serving as Principal Scientist at Abdera Therapeutics since December 2022, Bernd previously held positions as Senior Scientist in Analytical Chemistry and worked as a self-employed consultant from 2015 to 2022. Career highlights include a role as Senior Research Scientist at Numinus Bioscience and various academic positions at The University of British Columbia, Queen's University, and the University of Alberta, including Laboratory Coordinator at the Alberta Cancer Board Proteomics Centre. Bernd earned a Ph.D. in Analytical Chemistry from the University of Alberta and holds a Dipl. Ing. from Reutlingen University. Areas of expertise include advanced analytical technologies with a focus on pesticide analysis in complex matrices.
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.